Pfizer's Avastin biosimilar gets US approval

28 June 2019
pfizer-logo-big

Another biosimilar of one of the world’s best-selling oncology drugs, Avastin (bevacizumab), has been approved by the US Food and Drug Administration (FDA).

Pfizer’s (NYSE: PFE) Zirabev (bevacizumab-bvzr), a copy of Roche’s (ROG: SIX) original biologic, received approval for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

The first Avastin biosmilar, Mvasi (bevacizumab-awwb), from Amgen (Nasdaq: AMGN) and Allergan (NYSE: AGN), was approved by the FDA in September 2017, but it has still not been launched.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars